Structural basis of spirolactone recognition by the mineralocorticoid receptor

Molecular Pharmacology

Volumn 72, Issue 3, 2007, Pages 563-571

  Huyet, Jessica ^b   Pinon, Grégory M ^b   Fay, Michel R ^b   Fagart, Jérôme ^b   Rafestin Oblin, Marie Edith ^a  

^a CENTRE DE RECHERCHE BIOMÉDICALE BICHAT BEAUJON CRB3   (France)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; GLUTAMINE; MINERALOCORTICOID RECEPTOR; SPIRONOLACTONE;

ARTICLE; CONTROLLED STUDY; CRYSTAL STRUCTURE; CRYSTALLIZATION; DRUG POTENCY; DRUG STRUCTURE; EMBRYO; HUMAN; HUMAN CELL; LIGAND BINDING; PRIORITY JOURNAL;

AMINO ACID SUBSTITUTION; ARGININE; ASPARAGINE; BINDING SITES; CELL LINE; CRYSTALLOGRAPHY, X-RAY; GLYCINE; HUMANS; HYDROGEN BONDING; KIDNEY; LIGANDS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY; RECEPTORS, MINERALOCORTICOID; SPIRONOLACTONE; STRUCTURE-ACTIVITY RELATIONSHIP; TIME FACTORS; TRANS-ACTIVATION (GENETICS); TRANSFECTION;

EID: 34548297023     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.107.036459     Document Type: Article

References (38)

1. Bledsoe RK, Madauss KP, Holt JA, Apolito CJ, Lambert MH, Pearce KH, Stanley TB, Stewart EL, Trump RP, Willson TM, and Williams SP (2005) A ligand-mediated hydrogen bond network required for the activation of the mineralocorticoid receptor. J Biol Chem 280:31283-31293.
2. Bonvalet JP (1998) Regulation of sodium transport by steroid hormones. Kidney Int Suppl 65:S49-S56.
3. Brünger AT, Adams PD, Clore GM, DeLano WL, Gros P, Grosse-Kunstleve RW, Jiang JS, Kuszewski J, Nilges M, Pannu NS, et al. (1998) Crystallography and NMR system: A new software suite for macromolecular structure determination. Acta Crystallogr D Biol Crystallogr 54:905-921.
4. Corvol P, Claire M, Rafestin-Oblin ME, Michaud A, Roth-Meyer C, and Menard J (1977) Spirolactones: clinical and pharmacologic studies. Adv Nephrol Necker Hosp 7:199-215.
5. Couette B, Fagart J, Jalaguier S, Lombes M, Souque A, and Rafestin-Oblin ME (1996) Ligand-induced conformational change in the human mineralocorticoid receptor occurs within its hetero-oligomeric structure. Biochem J 315:421-427.
6. de Gasparo M, Joss U, Ramjoue HP, Whitebread SE, Haenni H, Schenkel L, Kraehenbuehl C, Biollaz M, Grob J, and Schmidlin J (1987) Three new epoxy-spirolactone derivatives: characterization in vivo and in vitro. J Pharmacol Exp Ther 240:650-656.
7. de Wet JR, Wood KV, Deluca M, Helinski DR, and Subramani S (1987) Firefly luciferase gene: structure and expression in mammalian cells. Mol Cell Biol 7:725-737.
8. Elger W, Beier S, Pollow K, Garfield R, Shi SQ, and Hillisch A (2003) Conception and pharmacodynamic profile of drospirenone. Steroids 68:891-905.
9. Fagart J, Wurtz JM, Souque A, Hellal-Levy C, Moras D, and Rafestin-Oblin ME (1998) Antagonism in the human mineralocorticoid receptor. EMBO J 17:3317-3325.
10. Fagart J, Seguin C, Pinon GM, and Rafestin-Oblin ME (2005a) The Met852 residue is a key organizer of the ligand-binding cavity of the human mineralocorticoid receptor. Mol Pharmacol 67:1714-1722.
11. Fagart J, Huyet J, Pinon GM, Rochel M, Mayer C, and Rafestin-Oblin ME (2005b) Crystal structure of a mutant mineralocorticoid receptor responsible for hypertension. Nat Struct Mol Biol 12:554-555.
12. Fejes-Tóth G, Pearce D, and Naray-Fejes-Toth A (1998) Subcellular localization of mineralocorticoid receptors in living cells: effects of receptor agonists and antagonists. Proc Natl Acad Sci U S A 95:2973-2978.
13. Garthwaite SM and McMahon EG (2004) The evolution of aldosterone antagonists. Mol Cell Endocrinol 217:27-31.
14. Geller DS, Farhi A, Pinkerton N, Fradley M, Moritz M, Spitzer A, Meinke G, Tsai FT, Sigler PB, and Lifton RP (2000) Activating mineralocorticoid receptor mutation in hypertension exacerbated by pregnancy. Science 289:119-123.
15. Gouilleux F, Sola B, Couette B, and Richard-Foy H (1991) Cooperation between structural elements in hormono-regulated transcription from the mouse mammary tumor virus promoter. Nucleic Acids Res 19:1563-1569.
16. Gronemeyer H, Gustafsson JA, and Laudet V (2004) Principles for modulation of the nuclear receptor superfamily. Nat Rev Drug Discov 3:950-964.
17. Hellal-Levy C, Fagart J, Souque A, and Rafestin-Oblin ME (2000) Mechanistic aspects of mineralocorticoid receptor activation. Kidney Int 57:1250-1255.
18. Herbomel P, Bourachot B, and Yaniv M (1984) Two distinct enhancers with different cell specificities coexist in the regulatory region of polyoma. Cell 39:653-662.
19. Horisberger JD and Rossier BC (1992) Aldosterone regulation of gene transcription leading to control of ion transport. Hypertension 19:221-227.
20. Hultman ML, Krasnoperova NV, Li S, Du S, Xia C, Dietz JD, Lala DS, Welsch DJ, and Hu X (2005) The ligand-dependent interaction of mineralocorticoid receptor with coactivator and corepressor peptides suggests multiple activation mechanisms. Mol Endocrinol 19:1460-1473.
21. Jones TA, Zou JY, Cowan SW, and Kjeldgaard M (1991) Improved methods for building protein models in electron density maps and the location of errors in these models. Acta Crystallogr A 47:110-119.
22. Kabsch W (1993) Automatic processing of rotation diffraction data from crystals of initially unknown symmetry and cell constants. J Appl Crystallogr 26:795-800.
23. Kleywegt GJ and Jones TA (1994) Detection, delineation, measurement and display of cavities in macromolecular structures. Acta Crystallogr D Biol Crystallogr 50:178-185.
24. Laskowski RA, MacArthur MW, Moss DS, and Thornton JM (1993) PROCHECK: a program to check the stereochemical quality of protein structures. J Appl Crystallogr 26:283-291.
25. Li Y, Suino K, Daugherty J, and Xu HE (2005) Structural and biochemical mechanisms for the specificity of hormone binding and coactivator assembly by mineralocorticoid receptor. Mol Cell 19:367-380.
26. Mangelsdorf DJ, Thummel C, Beato M, Herrlich P, Schutz G, Umesono K, Blumberg B, Kastner P, Mark M, Chambon P, et al. (1995) The nuclear receptor superfamily: the second decade. Cell 83:835-839.
27. Nagy L and Schwabe JW (2004) Mechanism of the nuclear receptor molecular switch. Trends Biochem Sci 29:317-324.
28. Nickisch K, Bittler D, Casals-Stenzel J, Laurent H, Nickolson R, Nishino Y, Petzoldt K, and Wiechert R (1985) Aldosterone antagonists. 1. Synthesis and activities of 6 beta,7 beta:15 beta,16 betadimethylene steroidal spirolactones. J Med Chem 28: 546-550.
29. Penfornis P, Viengchareun S, Le Menuet D, Cluzeaud F, Zennaro MC, and Lombes M (2000) The mineralocorticoid receptor mediates aldosterone-induced differentiation of T37i cells into brown adipocytes. Am J Physiol Endocrinol Metab 279: E386-E394.
30. Pinon GM, Fagart J, Souque A, Auzou G, Vandewalle A, and Rafestin-Oblin ME (2004) Identification of steroid ligands able to inactivate the mineralocorticoid receptor harboring the S810L mutation responsible for a severe form of hypertension. Mol Cell Endocrinol 217:181-188.
31. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, and Wittes J (1999) The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 341:709-717.
32. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, and Gatlin M; Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators (2003) Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 348:1309-1321.
33. + absorption in mammalian principal cortical collecting duct cells. Mol Pharmacol 62:1306-1313.
34. Rafestin-Oblin ME, Souque A, Bocchi B, Pinon G, Fagart J, and Vandewalle A (2003) The severe form of hypertension caused by the activating S810L mutation in the mineralocorticoid receptor is cortisone related. Endocrinology 144:528-533.
35. Rossi G, Boscaro M, Ronconi V, and Funder JW (2005) Aldosterone as a cardiovascular risk factor. Trends Endocrinol Metab 16:104-107.
36. Souque A, Fagart J, Couette B, Davioud E, Sobrio F, Marquet A, and Rafestin-Oblin ME (1995) The mineralocorticoid activity of progesterone derivatives depends on the nature of the C18 substituent. Endocrinology 136:5651-5658.
37. Storoni LC, McCoy AJ, and Read RJ (2004) Likelihood-enhanced fast rotation functions. Acta Crystallogr D Biol Crystallogr 60:432-438.
38. Trapp T and Holsboer F (1995) Ligand-induced conformational changes in the mineralocorticoid receptor analyzed by protease mapping. Biochem Biophys Res Commun 215:286-291.